Eduovisual
Human Development
Geriatric urinary incontinence and frailty
— Under-reported: only ~50% of affected elders volunteer symptoms; screen actively at annual Medicare wellness visits and any frailty/falls assessment.
— Independent predictor of nursing home placement, depression, skin breakdown, and recurrent UTIs.
— Modifiable in most cases without urology referral — primary care owns initial workup and lifestyle/behavioral first-line therapy.
— Any older adult presenting with falls, nocturia, recurrent UTI, perineal dermatitis, sleep disturbance, social withdrawal, or caregiver report of "wet pads."
— New incontinence in a previously continent elder = always investigate for a reversible trigger (delirium, infection, medication, mobility loss) before labeling chronic.
— Incontinence is one of the "Geriatric Giants" (instability, immobility, intellectual impairment, incontinence, iatrogenesis).
— Fried frailty phenotype (weight loss, exhaustion, weakness, slow gait, low activity) shares pathophysiology — sarcopenia of pelvic floor + detrusor dysfunction + cognitive slowing of toileting cues.
— Delirium, Infection (symptomatic UTI), Atrophic vaginitis/urethritis, Pharmaceuticals, Psychological (depression), Excess urine output (CHF, hyperglycemia, hypercalcemia), Restricted mobility, Stool impaction.
Board pearl: On Step 3, new-onset incontinence in a hospitalized or recently discharged elder is delirium or fecal impaction until proven otherwise — order a rectal exam and mental status check before prescribing an anticholinergic.
— Stress incontinence: small-volume leaks with cough, sneeze, laugh, lifting; multiparous women, post-prostatectomy men. Pelvic floor laxity or sphincter incompetence.
— Urge incontinence (OAB): sudden urgency followed by large-volume loss; "key-in-door," running-water triggers; nocturia ≥2; detrusor overactivity. Most common in elders.
— Mixed: features of both — most prevalent pattern in women >70.
— Overflow: continuous dribbling, hesitancy, weak stream, sensation of incomplete emptying; BPH, diabetic autonomic neuropathy, anticholinergic use, spinal cord pathology.
— Functional: intact urinary tract but cognitive or mobility barrier (dementia, arthritis, restraints, inaccessible bathroom).
— Voiding diary for 3 days: frequency, volume, leakage triggers, fluid intake, caffeine/alcohol.
— Symptom onset: abrupt (think reversible/DIAPPERS) vs gradual (chronic structural).
— Obstetric/surgical: vaginal deliveries, hysterectomy, prostate surgery, pelvic radiation.
— Medication review is non-negotiable: diuretics (volume), α-blockers (sphincter relaxation → stress in women), anticholinergics/opioids (retention/overflow), sedatives (functional), SGLT2 inhibitors (polyuria), cholinesterase inhibitors (urge).
— Bowel history: constipation worsens all types; fecal incontinence often coexists.
— Functional/cognitive: can the patient reach the toilet in <1 minute? MoCA or Mini-Cog.
— Goals of care: containment vs cure — frail elder with dementia may prioritize dignity/skin integrity over cystometry.
Key distinction: Leakage with urgency = urge; leakage without any warning = stress or overflow. A patient who leaks while sleeping (no warning, supine) suggests overflow from chronic retention, not stress.
Step 3 management: Always reconcile the med list before ordering urodynamics — deprescribing a bladder-active drug resolves up to 30% of late-life incontinence.
— Gait speed (<0.8 m/s over 4 m) and Timed Up and Go (>12 s) — predicts both falls and functional incontinence.
— Cognitive screen: Mini-Cog or MoCA; if impaired, expect functional component.
— Volume status: JVD, edema, crackles — CHF-driven nocturnal polyuria mimics urge incontinence.
— Suprapubic dullness/palpable bladder → urinary retention (overflow).
— Constipation/impaction mass in LLQ.
— Atrophic vaginitis: pale, thin, friable mucosa, loss of rugae → contributes to urge and recurrent UTI.
— Prolapse: cystocele, rectocele, uterine descent; grade with Valsalva.
— Cough stress test with comfortably full bladder: instantaneous leak with cough confirms stress incontinence (>90% specific).
— Pelvic floor strength: ask patient to squeeze around examining finger (Kegel assessment).
— DRE for prostate size, nodules, sphincter tone.
— Perineal sensation and bulbocavernosus reflex — absent reflex suggests sacral cord/neuropathy → overflow.
— Saddle anesthesia, lower-extremity weakness, hyperreflexia → cord pathology (cauda equina, MS, cervical myelopathy from spondylosis in elders).
— Resting tremor, bradykinesia → Parkinson's (urge incontinence common).
— Sacral, perineal, inner-thigh moisture-associated dermatitis or stage I–II pressure injury = chronic, poorly managed incontinence and a quality indicator.
Board pearl: A palpable bladder + dribbling + diabetes/anticholinergic use = overflow incontinence — measure a post-void residual before anything else; never give an antimuscarinic empirically.
CCS pearl: In a CCS case of a frail elder with new incontinence, order vitals, mental status, abdominal exam, rectal exam, pelvic/GU exam, gait assessment, and skin check on the same clock tick — this earns full physical-exam credit and uncovers DIAPPERS triggers.
— Urinalysis ± urine culture: rule out symptomatic UTI, hematuria, glucosuria. Asymptomatic bacteriuria in elders is not treated even if incontinent unless other UTI symptoms exist.
— Post-void residual (PVR) by bladder scan within 10 min of void: <50 mL normal; 50–200 mL borderline; >200 mL abnormal → suggests retention/overflow, contraindicates antimuscarinics.
— Basic metabolic panel + glucose/HbA1c + calcium: uncover polyuria from hyperglycemia or hypercalcemia.
— TSH if other features of thyroid disease.
— 3-day bladder diary: the single highest-yield "test" — quantifies frequency, functional bladder capacity, nocturnal polyuria (>33% of 24-h output overnight).
— Microscopic hematuria (>3 RBC/hpf) in a smoker or age >60 → CT urography + cystoscopy to exclude urothelial malignancy. Don't anchor on "it's just incontinence."
— High PVR + diabetes → diabetic cystopathy (autonomic neuropathy).
— High PVR + saddle anesthesia → cauda equina, emergent MRI.
— High PVR + new medication → drug-induced retention (anticholinergics, opioids, antihistamines, decongestants).
— Routine urodynamics, cystoscopy, or imaging for uncomplicated stress or urge incontinence.
Key distinction: Asymptomatic bacteriuria vs UTI in elders — pyuria + positive culture alone do NOT justify antibiotics; require new dysuria, suprapubic pain, gross hematuria, fever, or acute mental status change. Treating asymptomatic bacteriuria drives resistance and C. difficile.
Step 3 management: Bladder diary + UA + PVR + med reconciliation = the four-pronged baseline that earns nearly every point on incontinence vignettes.
— Diagnostic uncertainty after history, exam, UA, PVR, and diary.
— Failed 8–12 weeks of behavioral + first-line pharmacotherapy.
— Hematuria, recurrent UTIs (≥2 in 6 mo or ≥3 in 12 mo), pelvic pain, prior pelvic radiation or surgery.
— Significant prolapse (beyond hymen), suspected fistula (continuous leakage post-hysterectomy/radiation), or neurogenic bladder.
— Considering surgical intervention or third-line therapy (Botox, neuromodulation).
— Uroflowmetry: flat/prolonged curve → obstruction or detrusor underactivity.
— Cystometry: measures detrusor pressure and capacity; identifies detrusor overactivity, low compliance, sensory urgency.
— Pressure-flow study: differentiates bladder outlet obstruction from detrusor underactivity in men with overflow.
— EMG: detrusor-sphincter dyssynergia (MS, spinal cord injury).
— Renal/bladder US if elevated PVR with renal dysfunction (rule out hydronephrosis).
— MRI lumbosacral spine if new incontinence with neuro signs — cauda equina, cord compression, MS plaques.
— Pelvic MRI for complex prolapse or fistula mapping.
Board pearl: Continuous urinary leakage in a woman after hysterectomy or pelvic radiation = vesicovaginal fistula until proven otherwise — confirm with tampon dye test or cystoscopy, not urodynamics.
Step 3 management: Don't send a frail nursing-home resident with dementia for urodynamics — the test won't change management because behavioral/containment strategies dominate. Reserve UDS for patients who are surgical candidates or have a confusing neurogenic picture.
— Stop or substitute offending drugs: switch α-blocker tamsulosin causing stress leakage in a woman (rare but tested); replace oxybutynin (anticholinergic burden) with mirabegron; minimize loop diuretics late in day.
— Treat symptomatic UTI; relieve fecal impaction; optimize CHF; control hyperglycemia; restore mobility.
— Weight loss of 5–10% reduces stress incontinence episodes by ~50%.
— Caffeine reduction to <200 mg/day; limit evening fluids; cap total intake at 1.5–2 L unless contraindicated.
— Bladder training: scheduled voiding every 2–3 h, gradually extending intervals (urge).
— Prompted/timed voiding for cognitively impaired elders — caregiver-driven, every 2 h.
— Pelvic floor muscle training (Kegels): 8–12 contractions × 3 sets daily × 15–20 weeks; add biofeedback or physical therapy referral for best results. First-line for stress and mixed; also benefits urge.
— Smoking cessation (reduces cough-driven stress leakage).
— Constipation management.
— Stress → PFMT → pessary/incontinence ring → midurethral sling.
— Urge → PFMT + bladder training → β3-agonist or antimuscarinic → Botox/PTNS/sacral neuromodulation.
— Mixed → treat the most bothersome component first (usually urge).
— Overflow → relieve obstruction (α-blocker, 5-ARI, TURP) or catheterize (CIC > indwelling) for detrusor underactivity.
— Functional → environmental modifications, bedside commode, scheduled toileting, caregiver support.
CCS pearl: On a CCS case, order "patient education — bladder diary, pelvic floor exercises, caffeine reduction" early; behavioral interventions are reimbursable and high-yield even before pharmacotherapy.
Key distinction: ACP guidelines explicitly recommend PFMT before drugs for stress, urge, and mixed incontinence in women — drug-first is a wrong answer.
— β3-adrenergic agonists — mirabegron 25–50 mg daily or vibegron 75 mg daily: preferred in elders because they avoid anticholinergic cognitive burden. Side effects: HTN (check BP), tachycardia; avoid uncontrolled HTN.
— Antimuscarinics: oxybutynin, tolterodine, solifenacin, darifenacin, trospium, fesoterodine. Block M2/M3 detrusor receptors.
· Avoid oxybutynin IR in elders (Beers criteria) — highest CNS penetration, linked to dementia incidence in cumulative-exposure studies.
· Preferred if antimuscarinic needed: trospium (quaternary amine, doesn't cross BBB) or darifenacin (M3-selective).
— Counsel: 4–8 weeks to assess effect; dry mouth, constipation, blurred vision, urinary retention. Check PVR before starting if any retention risk.
— No FDA-approved drug in the US; duloxetine used off-label/in Europe.
— Vaginal estrogen (cream, ring, tablet) for postmenopausal women with atrophic vaginitis — improves urge and recurrent UTI; safe even in many breast cancer survivors after shared decision-making. Systemic estrogen worsens incontinence — do not use.
— α1-blockers (tamsulosin, alfuzosin) for symptomatic relief; watch orthostasis and floppy iris.
— 5α-reductase inhibitors (finasteride, dutasteride) for prostate >40 g; 6-month onset.
— Combination if large prostate and moderate–severe symptoms.
— Address CHF, OSA, evening fluid intake; desmopressin is generally avoided ≥65 (hyponatremia risk, Beers).
— Calculate cumulative ACB score; aim for ≤2. Deprescribe diphenhydramine, TCAs, paroxetine, hyoscyamine.
Board pearl: In a 78-year-old with mild cognitive impairment and urge incontinence, mirabegron beats oxybutynin — the latter accelerates cognitive decline and is Beers-listed.
Step 3 management: Recheck PVR after starting an antimuscarinic in an at-risk patient; new retention with abdominal distention is a board-favorite adverse event.
— Pessary or incontinence ring: vaginal device for women preferring nonsurgical option; fit in office, clean every 2–3 months. Excellent for frail elders.
— Pelvic floor PT with biofeedback.
— Urethral bulking agents (collagen, calcium hydroxylapatite): outpatient, modest durability — useful when surgery is high-risk.
— Midurethral sling (TVT/TOT): gold standard, ~80% cure; mesh complications discussed in informed consent.
— Burch colposuspension if mesh declined.
— Artificial urinary sphincter: standard for post-prostatectomy stress incontinence in men.
— Onabotulinumtoxin A 100 U intradetrusor injection: lasts 6–9 months; risk of urinary retention requiring intermittent catheterization (~6%) — counsel and ensure patient can perform CIC.
— Percutaneous tibial nerve stimulation (PTNS): 30-min weekly office sessions × 12, then maintenance; minimal side effects, ideal for frail elders.
— Sacral neuromodulation (InterStim): implanted lead at S3; good for refractory urge and non-obstructive retention.
— TURP remains standard; alternatives include holmium laser enucleation (HoLEP), prostatic urethral lift (UroLift), water vapor therapy (Rezūm) — lower morbidity in frail men.
— Clean intermittent catheterization (CIC) preferred over indwelling Foley for chronic retention — fewer UTIs, less urosepsis, preserves urethral integrity.
— Stage III/IV sacral pressure injury needing dry field, terminal/palliative comfort, refractory retention without CIC capability, accurate I/Os in critical illness. Convenience is never an indication.
Key distinction: Botox causes retention; mirabegron causes hypertension; antimuscarinics cause cognitive impairment and dry mouth — match the adverse event to the drug.
CCS pearl: Order "urology consult" only after documenting failure of behavioral + ≥1 pharmacotherapy trial; premature consult costs points.
— Use the "4 M's": What Matters, Medications, Mentation, Mobility. Align incontinence care with patient priorities — a hospice patient values dignity and skin integrity, not cystometry.
— Frailty index ≥0.25 or Clinical Frailty Scale ≥6 → favor containment, scheduled toileting, caregiver education over surgery or polypharmacy.
— Avoid antimuscarinics; cholinesterase inhibitors (donepezil) can paradoxically worsen urge incontinence — do not add antimuscarinic on top ("prescribing cascade").
— Prompted voiding every 2 h is evidence-based for nursing home dementia patients.
— Trospium: renally cleared, dose-reduce or avoid if CrCl <30.
— Mirabegron: avoid if eGFR <15 or severe hepatic impairment; reduce dose 25 mg if eGFR 15–29 or Child-Pugh B.
— Solifenacin, darifenacin, fesoterodine: max 5 mg in severe renal/hepatic disease.
— Tamsulosin: generally safe; alfuzosin needs caution with hepatic disease.
— Avoid darifenacin and solifenacin in Child-Pugh C.
— Duloxetine contraindicated in hepatic disease/heavy alcohol use.
— Avoid: oxybutynin IR, diphenhydramine, hyoscyamine, TCAs, first-generation antihistamines, benzodiazepines, sliding-scale insulin, desmopressin (≥65).
— STOPP/START criteria flag long-term Foleys without indication and prescribing cascades.
— Nocturia + sedative + orthostasis from α-blocker = hip fracture cocktail; review at every visit.
Board pearl: A demented elder in long-term care with worsening urge incontinence shortly after starting donepezil — the answer is prompted voiding and continue donepezil for cognition, not adding oxybutynin (prescribing cascade trap).
Step 3 management: Always check eGFR before mirabegron or antimuscarinic dosing in elders; renal function changes silently with sarcopenia.
— De novo stress incontinence after vaginal delivery resolves spontaneously in most by 12 months; PFMT antenatally and postpartum reduces persistence.
— Persistent symptoms beyond 6 months → formal evaluation.
— Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, recurrent UTIs, urge incontinence.
— First-line: vaginal estrogen (low-dose cream, ring, or tablet). Safe; does not require progestin; FDA black box has been re-examined and many oncologists permit use in select breast cancer survivors after shared decision-making with oncology.
— Non-hormonal: vaginal moisturizers, lubricants, ospemifene (SERM), prasterone (DHEA).
— Predominantly stress type from sphincter injury; expect partial recovery over 6–12 months.
— Early PFMT (initiated preoperatively when feasible) accelerates continence.
— Persistent at 12 months → male sling (mild–moderate) or artificial urinary sphincter (moderate–severe).
— Urge incontinence after prostatectomy or radiation suggests detrusor overactivity or radiation cystitis — workup with cystoscopy.
— Parkinson's: urge incontinence dominant; carbidopa-levodopa optimization may help; avoid anticholinergics that worsen cognition.
— MS: detrusor-sphincter dyssynergia — CIC + antimuscarinic/Botox; monitor upper tracts with renal US annually.
— Spinal cord injury above T6: autonomic dysreflexia risk during bladder distention — emergency.
— Trans women on estrogen may experience pelvic floor changes; trans men post-hysterectomy may have stress patterns. Use anatomy-based, respectful history.
Key distinction: Vaginal estrogen treats incontinence and GSM; systemic estrogen (oral, transdermal) worsens incontinence (WHI data) — do not conflate.
Board pearl: New autonomic dysreflexia (HTN, headache, sweating above lesion) in a spinal-cord-injured patient = check for blocked catheter or full bladder first; relieve before antihypertensives.
— Incontinence-associated dermatitis (IAD): erythema, maceration, satellite lesions; differs from pressure injury (IAD spares bony prominences, follows urine/stool distribution).
— Progression to stage II–IV pressure injury, secondary bacterial/fungal infection (Candida).
— Prevention: barrier creams (zinc oxide, dimethicone), pH-balanced cleansers, prompt changes, avoid prolonged briefs.
— Recurrent UTI from incomplete emptying, high PVR, or atrophic vaginitis.
— Urosepsis risk markedly higher with chronic indwelling catheters (~3–5%/1000 catheter-days bacteremia).
— CAUTI is a CMS non-reimbursable hospital-acquired condition.
— Urgency-driven rushing to bathroom + nocturia + nocturnal orthostasis from drugs → hip fracture.
— Incontinence independently doubles fall risk in community-dwelling elders.
— Chronic overflow / neurogenic bladder → hydronephrosis → CKD; monitor renal US.
— Depression, anxiety, social isolation, sexual dysfunction, caregiver burnout — major drivers of nursing home placement.
— Cost: out-of-pocket pad/brief expenditures average $900–$2000/year; not covered by traditional Medicare (covered under some Medicare Advantage and Medicaid waivers).
— Antimuscarinic: cognitive decline, falls, constipation, urinary retention, narrow-angle glaucoma exacerbation, heat stroke (impaired sweating).
— Mirabegron: HTN, atrial arrhythmia, rare angioedema.
— α-blocker: orthostasis, intraoperative floppy iris syndrome (warn ophthalmologist before cataract surgery).
— Indwelling catheter: urethral erosion, bladder stones, squamous cell bladder cancer with chronic use >10 years.
Step 3 management: A patient on tamsulosin scheduled for cataract surgery → notify ophthalmology of floppy iris risk; do not stop the drug abruptly without coordination — this is a classic perioperative communication item.
Board pearl: Long-term indwelling Foley + new gross hematuria = evaluate for squamous cell carcinoma of bladder.
— Acute urinary retention with suprapubic pain, distended bladder → immediate catheterization, then evaluate cause (BPH, medication, fecal impaction, spinal cord).
— Cauda equina syndrome: new incontinence + saddle anesthesia + bilateral LE weakness + back pain → stat MRI lumbar spine, neurosurgery consult, within hours.
— Urosepsis: fever, hypotension, altered mentation, obstructed/infected system → fluids, blood/urine cultures, broad-spectrum antibiotics within 1 hour, urgent decompression (nephrostomy or stent) if obstruction.
— Autonomic dysreflexia in SCI patient: relieve bladder distention emergently.
— Acute kidney injury from bilateral hydronephrosis/obstruction → catheterize, consult urology.
— Microscopic or gross hematuria without infection.
— Suspected fistula (continuous leak post-surgery/radiation).
— Pelvic mass on exam.
— Suspected malignancy (smoker, weight loss, hematuria).
— Failed behavioral + first-line pharmacotherapy after ≥8–12 weeks.
— Significant prolapse beyond hymen.
— Recurrent UTI requiring workup.
— Complex neurogenic bladder.
— Consideration of surgery or third-line OAB therapy.
— Frail elder with multimorbidity, polypharmacy, or near end of life — reframe goals toward containment, dignity, caregiver support.
— Discuss avoiding burdensome workup when life expectancy <1–2 years.
CCS pearl: New incontinence + back pain + bilateral leg weakness — order MRI lumbar spine STAT, neurosurgery consult, and IV dexamethasone if metastatic compression is suspected; do not order urodynamics.
Key distinction: Acute retention (painful, distended bladder, can't void) ≠ overflow incontinence (chronic, often painless dribbling). Both need PVR but only acute retention is an emergency.
— Stress incontinence: sphincter/support failure. Leaks with exertion. Cough stress test positive. PVR normal.
— Urge incontinence (detrusor overactivity): sudden urgency, large leaks, nocturia. Often idiopathic; secondary to bladder stones, tumor, infection, neurologic disease.
— Mixed incontinence: both stress and urge components — most common in older women.
— Overflow incontinence: chronic retention from obstruction (BPH, stricture, prolapse) or detrusor underactivity (diabetes, anticholinergics, spinal cord). High PVR.
— Functional incontinence: intact tract; impaired mobility/cognition.
— Continuous incontinence: suggests fistula (vesicovaginal, ureterovaginal) or ectopic ureter (rare in adults). Post-hysterectomy or post-radiation history is the giveaway.
— Symptomatic UTI: dysuria, urgency, frequency, hematuria, suprapubic pain ± fever; treat and reassess incontinence afterward.
— Bladder cancer: painless hematuria + new urge symptoms in a smoker → cystoscopy.
— Bladder stones: intermittent stream, urgency, post-void dribbling; imaging diagnostic.
— Interstitial cystitis/bladder pain syndrome: pelvic pain with filling, relieved by voiding; pain is the dominant feature.
— Urethral diverticulum: post-void dribbling + dyspareunia + recurrent UTI in women; MRI diagnoses.
— Prostatitis: perineal pain, dysuria, urgency, fever (acute) or chronic pelvic pain.
— Pelvic organ prolapse without incontinence: vaginal bulge, pressure, may cause obstructive voiding (paradoxical retention).
Board pearl: Continuous dribbling day and night in a woman who had a hysterectomy 3 weeks ago = vesicovaginal fistula, not stress incontinence. Confirm with cystoscopy + dye test; refer to urogynecology.
Key distinction: Urgency + pelvic pain that improves with voiding = interstitial cystitis; urgency + leakage without pain = OAB.
— Uncontrolled diabetes: osmotic diuresis (polyuria) + autonomic neuropathy (detrusor underactivity, high PVR). HbA1c >9% commonly presents with new incontinence; tight control may reverse early.
— Hypercalcemia, diabetes insipidus: polyuria-driven urgency/leakage.
— Hypothyroidism: rare but causes detrusor underactivity.
— CHF: nocturnal polyuria from supine fluid mobilization. Treat with afternoon diuretic, leg elevation, compression stockings, sodium restriction — not antimuscarinics.
— Obstructive sleep apnea: ANP release → nocturia and nocturnal enuresis; CPAP can resolve it.
— Stroke: post-stroke detrusor overactivity (urge).
— Parkinson's, multiple system atrophy: urge dominant; MSA has earlier, more severe incontinence than idiopathic PD — useful clinical clue.
— MS: mixed urge + retention with dyssynergia.
— Normal pressure hydrocephalus (NPH): wet, wobbly, wacky — urinary incontinence + ataxic gait + dementia; large-volume LP improves gait → shunt.
— Cervical/lumbar spondylosis, cord compression, cauda equina: as above.
— Diabetic and alcoholic autonomic neuropathy: retention/overflow.
— Diuretics (volume), α-blockers (sphincter relaxation in women), opioids/anticholinergics (retention), sedatives (functional), SGLT2 inhibitors (osmotic), cholinesterase inhibitors (urge), ACE inhibitors (cough → stress).
— Physical restraints, inaccessible bathrooms, ill-fitting clothing, inadequate caregiver availability, post-op delirium.
Board pearl: Triad of gait apraxia + cognitive decline + urinary incontinence = normal pressure hydrocephalus; large-volume LP is both diagnostic and therapeutic trial before VP shunt.
Step 3 management: Before labeling "OAB," confirm HbA1c, calcium, BNP, and screen for OSA in the obese elder with prominent nocturia.
— Reconcile every bladder-active drug at discharge; document indication for any new antimuscarinic.
— Remove all unnecessary indwelling Foleys before discharge — CAUTI prevention bundle.
— Provide a written incontinence care plan: voiding schedule, fluid targets, PFMT instructions, skin care, when to call.
— Confirm caregiver availability and home toileting access (commode, raised seat, grab bars) before discharge of a frail elder; involve home PT/OT.
— Reassess antimuscarinics every 6–12 months; trial deprescribing if benefit unclear or cognition declines.
— Annual review of anticholinergic burden (ACB scale).
— Vaginal estrogen continues indefinitely if benefit; minimal systemic absorption.
— α-blockers: reassess after 6–12 weeks; combine with 5-ARI if prostate large and symptomatic.
— Continued PFMT — most benefit accrues over 3–6 months and is maintained with ongoing exercises.
— Bladder diary every 3–6 months to track progress.
— Weight maintenance, smoking cessation, constipation prevention (fiber, hydration, stool softener if needed).
— Influenza, pneumococcal, COVID-19, RSV (≥60) — reduce respiratory infections that drive cough and worsen stress incontinence.
— Shingrix to prevent zoster-related sacral neuropathy.
— Vitamin D 800 IU/day, calcium intake assessment, DXA per USPSTF.
— Home safety eval, night-light, bedside commode for nocturia.
— Review orthostatic BP at each visit.
Step 3 management: At every Medicare Annual Wellness Visit, document an incontinence screen + falls screen + cognitive screen + medication reconciliation — they cluster and are billable under G-codes.
CCS pearl: Before signing discharge orders, write "remove Foley" and "home health PT/OT, bedside commode, barrier cream" as standing items on geriatric admissions.
— 2–4 weeks after starting a new drug: assess efficacy, adverse effects, BP (mirabegron), PVR (antimuscarinic), cognition.
— 8–12 weeks: reassess after behavioral + first-line pharmacotherapy; escalate if <50% improvement.
— 6–12 months: routine maintenance, deprescribing review, bladder diary check, skin exam, caregiver burden screen (Zarit Burden Interview).
— Annual: renal function (especially neurogenic bladder), UA only if symptomatic, fall risk, cognition (Mini-Cog), depression (PHQ-2/9).
— Antimuscarinics: cognition (MoCA trend), PVR, constipation, IOP in glaucoma.
— Mirabegron: BP at each visit; ECG if palpitations.
— α-blockers: orthostatic vitals; warn before cataract surgery.
— Vaginal estrogen: annual pelvic exam, watch for unexplained vaginal bleeding.
— Botox: PVR at 2 weeks and 1 month; teach CIC pre-emptively.
— Indwelling catheter (if unavoidable): change q4–12 weeks, evaluate for removal at every visit.
— Normalize the conversation: "Many people your age have this — it's treatable."
— Set realistic expectations: 50–70% improvement is typical; complete dryness is not guaranteed.
— Teach Kegels correctly — "lift the muscles you'd use to stop urine flow" without buttock/abdominal contraction; verify with biofeedback or pelvic PT referral.
— Discuss containment products (absorbent pads, pull-ups, external catheters/PureWick) without shame.
— Address sexual function — incontinence during intercourse (coital incontinence) is common and treatable.
— Train on prompted voiding schedules, skin care, when to seek help; address burnout, respite care, adult day programs.
Board pearl: A patient on solifenacin returns with new confusion at 6 weeks — stop the drug, reassess cognition in 2 weeks; this is a classic delirium-from-anticholinergic vignette.
Step 3 management: PHQ-9 every visit — incontinence and depression are bidirectional; treating one improves the other.
— Procedures like sling, Botox, or sacral neuromodulation in elders require explicit capacity assessment. Capacity is decision-specific: a patient with mild dementia may still consent to a pessary trial but not to complex surgery.
— If capacity is lacking, engage the legally authorized surrogate (healthcare proxy → spouse → adult children per state hierarchy). Document the discussion and surrogate's understanding of risks (e.g., Botox-induced retention requiring CIC).
— In advanced dementia or end-stage frailty, prioritize comfort, dignity, and caregiver support over diagnostic workups (cystoscopy, urodynamics) that will not change management. Discuss with surrogate and document.
— Catheter "for convenience" violates CMS quality standards; long-term Foleys in nursing homes are a regulatory red flag and a major nosocomial infection driver.
— CAUTI is a hospital-acquired condition with non-reimbursement under CMS; bundles include daily necessity review, aseptic insertion, closed drainage, perineal care.
— Untreated severe incontinence-associated dermatitis, prolonged soiling, or use of restraints to manage incontinence may constitute elder neglect — physicians are mandated reporters to Adult Protective Services in all 50 states. Document objective findings.
— Bed rails and chair restraints to "prevent falls from urgency rushing" worsen functional incontinence, delirium, and skin breakdown; CMS prohibits non-medically-justified restraints.
— Use private exam rooms, gender-concordant chaperones when requested, and respectful language; avoid "diapers" — use "absorbent products" or "briefs."
— At discharge, explicitly communicate medication changes (especially anticholinergic deprescribing) to the receiving facility or PCP; failure is a Step 3 transition-of-care error.
Board pearl: A nursing home places a Foley "to keep the bed dry" in a continent patient — this is not a medical indication, violates CMS standards, and may trigger an APS report if part of broader neglect.
Step 3 management: Document capacity, surrogate involvement, and goals-of-care discussion in the chart for any invasive incontinence intervention in cognitively impaired elders.
— DIAPPERS = reversible causes; always exclude first.
— NPH triad = wet, wobbly, wacky → LP then shunt.
— Wet without warning, supine = overflow.
— Cough → leak = stress; key in door → leak = urge.
— Continuous leakage post-hysterectomy = vesicovaginal fistula.
— Mirabegron → check BP.
— Oxybutynin → Beers, cognitive decline.
— Tamsulosin → floppy iris in cataract surgery.
— Donepezil + oxybutynin → prescribing cascade (avoid).
— Vaginal estrogen → good; systemic estrogen → bad (worsens incontinence).
— PVR >200 mL = abnormal.
— Hematuria >3 RBC/hpf in elder smoker → CT urography + cystoscopy.
— Nocturnal polyuria = >33% of 24-h urine output overnight.
— 5–10% weight loss → ~50% reduction in stress incontinence episodes.
— Recurrent UTI = ≥2 in 6 mo or ≥3 in 12 mo.
— Catheter-day bacteriuria risk = ~5%/day.
— Fried phenotype (3/5 = frail), Clinical Frailty Scale (≥6 = frail), Edmonton Frail Scale.
— Frailty modifies the entire treatment ladder toward behavioral and containment.
— ACP: PFMT for stress, urge, mixed in women (over drugs).
— AUA OAB: behavioral → β3 agonist/antimuscarinic (mirabegron preferred in elders) → Botox/PTNS/SNM.
— AGS Beers: avoid oxybutynin IR, diphenhydramine, desmopressin ≥65.
— Painless hematuria + smoker → urothelial cancer.
— Chronic Foley >10 yr → SCC of bladder.
— Pelvic radiation → late fistula, hemorrhagic cystitis.
Board pearl: "Wet, wobbly, wacky" + enlarged ventricles on CT = NPH; do a large-volume LP and watch gait improve before committing to shunt.
Key distinction: Symptomatic UTI vs asymptomatic bacteriuria in elders — treat only with new dysuria, fever, suprapubic pain, hematuria, or acute mental status change plus pyuria/positive culture.
— 82-year-old woman in hospital day 3 with new urinary incontinence, on diphenhydramine for sleep, with hard stool on rectal exam. Answer: disimpact, stop diphenhydramine — not start an antimuscarinic.
— 76-year-old with mild cognitive impairment and urge incontinence; PCP starts oxybutynin and 6 weeks later patient is confused and falls. Answer: discontinue oxybutynin, switch to mirabegron.
— Diabetic man with constant dribbling, palpable bladder, PVR 450 mL. Answer: straight catheterize, evaluate for diabetic cystopathy/BPH; do not prescribe antimuscarinic.
— 70-year-old with new incontinence + saddle anesthesia + bilateral leg weakness + back pain. Answer: STAT MRI lumbar spine, neurosurgery consult.
— Continuous leakage day and night 3 weeks after hysterectomy. Answer: cystoscopy with dye test, urogynecology referral.
— Gait apraxia + cognitive decline + urinary incontinence + ventriculomegaly on CT. Answer: large-volume LP, then VP shunt if gait improves.
— Nursing home resident with chronic incontinence, positive urine culture, no new symptoms. Answer: no antibiotics.
— Patient on tamsulosin scheduled for cataract surgery. Answer: inform ophthalmologist of floppy iris syndrome risk.
— Nursing home places Foley to "keep skin dry." Answer: remove catheter, initiate prompted voiding and barrier cream; consider APS report if part of broader neglect.
— Postmenopausal woman with leakage on coughing; first step? Answer: pelvic floor muscle training, weight loss, treat atrophic vaginitis with vaginal estrogen — before sling or drug.
Board pearl: When the stem mentions anticholinergic + new confusion, the answer is deprescribe, not add another drug for delirium.
Step 3 management: Pattern-match to DIAPPERS first; the "newest" intervention is usually wrong if a reversible cause is sitting in the stem.
Geriatric urinary incontinence is a treatable geriatric syndrome — diagnose by phenotype (stress, urge, mixed, overflow, functional), reverse DIAPPERS triggers first, layer pelvic floor and behavioral therapy before any drug, prefer mirabegron over oxybutynin in elders, and align intensity of workup and intervention with frailty and goals of care.
— Always exclude reversible causes first: Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychological, Excess output (CHF/DM/hyperCa), Restricted mobility, Stool impaction. Med reconciliation and rectal exam beat urodynamics on day one.
— Diagnose by phenotype, not by test: history + voiding diary + cough stress test + PVR + UA identify stress vs urge vs overflow vs functional in >90% of cases; reserve urodynamics and cystoscopy for refractory, hematuric, or surgical-candidate patients.
— Behavioral and lifestyle therapy is first-line for all phenotypes per ACP and AUA — PFMT, bladder training, weight loss, caffeine reduction, prompted voiding. Vaginal (not systemic) estrogen for postmenopausal urge and atrophic vaginitis. Drugs come second: mirabegron > antimuscarinics in elders because of Beers/cognitive risk; α-blockers and 5-ARIs for BPH overflow; surgery (sling, AUS, Botox, SNM) for refractory cases.
— Frailty changes everything: in advanced dementia or end-stage frailty, the right answer is containment, dignity, prompted voiding, skin care, and caregiver support — not cystoscopy. Avoid catheters-for-convenience (CAUTI, CMS non-reimbursement, possible elder neglect). Coordinate transitions of care explicitly, deprescribe anticholinergics, integrate falls and depression screening at every visit.
Board pearl: When in doubt, the Step 3 answer to a geriatric incontinence vignette is usually stop a drug, treat constipation, start Kegels, or remove the Foley — not order an advanced test or start a new medication.